SphingoTec has raised EUR 5 million (~USD 5.5 million) in a Series C round led by Think.Health Ventures, with participation from existing investors such as Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners.
The funds will be directed to further its market development, advance out-licensing activities, and facilitate strong cooperation with licensees. The company also plans to diversify its biomarker-based diagnostic solutions and enhance patient management in critical care.
Germany-based SphingoTec is a diagnostic company focused on developing innovative critical care biomarkers for diagnosing, predicting, and monitoring acute medical conditions. Its proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for assessing kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for assessing endothelial function in conditions like sepsis.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.